How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes.
about
Concepts and clinical use of ultra-long basal insulinCommon standards of basal insulin titration in type 2 diabetesPharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.Identifying and meeting the challenges of insulin therapy in type 2 diabetes.Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A1chieve studyA review of the pharmacological properties of insulin degludec and their clinical relevance.The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 DiabetesUncovering undetected hypoglycemic eventsLow within- and between-day variability in exposure to new insulin glargine 300 U/ml.Future of newer basal insulinHypoglycemia: The neglected complicationIatrogenic hypoglycemia in patients with type 2 diabetes: comparison of insulin analog premixes and human insulin premixes.Evolution of insulin development: focus on key parameters.Insulin detemir: a review of its use in the management of diabetes mellitus.Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus.Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice.The use of insulin detemir during pregnancy: a safety evaluation.Towards a Physiological Prandial Insulin Profile: Enhancement of Subcutaneously Injected Prandial Insulin Using Local Warming Devices.Moving toward the ideal insulin for insulin pumps.Half-life extended biotherapeutics.A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.Insulin treatment of type 2 diabetes: considerations when converting from human insulin to insulin analogs.Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.Switching basal insulins in type 2 diabetes: practical recommendations for health care providers.Advances in Basal Insulin Therapy.
P2860
Q26770354-CBB1834A-01B9-4B73-8766-32E3FA5B9B08Q27009355-CFA72C95-FC74-49D5-8E5D-61682EDEC370Q30248803-0002CAA0-EF01-4E32-868E-0FF80ED9637DQ33863413-14C30222-3ABB-44EA-AFF4-0F5B11837AF5Q34229076-1ECD20C0-5280-4D0B-8ED0-B5CD427760DDQ34436383-D83A98B6-2869-4BD2-B161-31F5909221F8Q35894512-699D76B6-CC65-4656-ADB6-47C05F75D296Q35922100-9CDA4AEC-CFB1-4128-8E92-7E99E2889E92Q36361469-0CC91D46-FF77-42F0-B3CF-E78FAA2A1B45Q36930701-E7BF8049-9B44-402A-B11A-4DD6D1C37D41Q37201653-583213F2-354A-4988-AB7D-FF7D0066FDAAQ37890773-90B36B41-8158-47A4-A0A9-2F5B27C3D36FQ38030454-A74C330B-216A-4776-8FAF-576309A13F90Q38056540-99D9B06D-821A-45A6-9B01-0D35EA72DA62Q38085657-DFEEF1AD-3CD4-4566-97B1-021D4F0CAD5EQ38101891-12B688A0-A4A2-4C08-93A0-1FD2ADDD8D20Q38176677-CAB0C623-128F-45FC-8CC1-0B2569520DE7Q38366782-A5648C9A-096F-43C3-85B5-4F13AE2F70C5Q38578266-027C79E0-A4CB-4DCF-8FF2-02EE6D396539Q38631154-F7E0FC76-5442-48F0-BA3C-8260ED6879C7Q38770067-3523544F-2985-4660-BB4A-89AB8A66A0AFQ38970550-88F17ACE-2180-4F23-AF4A-A40935896896Q44910855-49607302-DA34-40B1-9140-FE73CEFAAD7BQ46199321-2E20D2CA-3304-4BE1-9806-459DC3119F74Q48088343-3D1FF106-68E4-4F21-BF63-84CF01CFC724Q55309585-9706F52D-FFAA-4842-8761-6AC9B8F8CCB9
P2860
How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
How pharmacokinetic and pharma ...... in therapy in type 2 diabetes.
@en
How pharmacokinetic and pharma ...... in therapy in type 2 diabetes.
@nl
type
label
How pharmacokinetic and pharma ...... in therapy in type 2 diabetes.
@en
How pharmacokinetic and pharma ...... in therapy in type 2 diabetes.
@nl
prefLabel
How pharmacokinetic and pharma ...... in therapy in type 2 diabetes.
@en
How pharmacokinetic and pharma ...... in therapy in type 2 diabetes.
@nl
P2093
P2860
P921
P1476
How pharmacokinetic and pharma ...... in therapy in type 2 diabetes.
@en
P2093
P2860
P304
P356
10.1111/J.1742-1241.2010.02470.X
P5008
P577
2010-07-05T00:00:00Z
2010-09-01T00:00:00Z